Imaging in Semaglutide Study

Part of paid clinical trials in Cleveland, Ohio.

Sponsor: The Cleveland Clinic
Study ID: NCT07695454
Status: Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

BMI Greater Than 30
Type 2 Diabetes

Eligibility Criteria

Sex: ALL
Age: 45 Years - 75 Years
Healthy Volunteers: Not accepted

Interventions

31P-MRS and MRI — RADIATION
31P-MRS and MRI for patients with Type 2 Diabetes and obesity prescribed to semaglutide therapy

Study Details

In this preliminary observation study, the investigators will assess muscle function in terms of muscle strength and leverage imaging (MRI) and spectroscopy (31P-MRS) based techniques to assess longitudinal changes in muscle volume, quality and metabolic function in patients with T2D and obesity prescribed to semaglutide therapy. The patients will be evaluated at three time points: 1) baseline, 2) 3-month and 3) 6-month after the therapy. These longitudinal changes will then be compared and correlated with changes in physical measurements such as BMI and patient reported outcome measures (PROMs). The primary aim of our study is to investigate the longitudinal effects of semaglutide therapy on patients with T2D and obesity, on skeletal muscle strength, muscle volume, quality and metabolic function.